Ticker,Title,Link
FATE,Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE),8/22/2024 10:20:26 AM
FATE,Fate Therapeutics’ Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522,8/20/2024 6:45:36 AM
FATE,Fate Therapeutics (FATE) Gets a Hold from Stifel Nicolaus,8/19/2024 2:15:17 AM
FATE,Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress,8/16/2024 6:31:09 AM
FATE,Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE),8/14/2024 12:16:06 PM
FATE,TD Cowen Reaffirms Their Hold Rating on Fate Therapeutics (FATE),8/13/2024 10:15:25 PM
FATE,Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),8/2/2024 10:01:00 PM
FATE,"Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors",7/31/2024 2:00:00 PM
FATE,Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),7/2/2024 10:01:00 PM
FATE,Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts,6/17/2024 10:00:28 PM
FATE,Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),6/4/2024 10:01:00 PM
FATE,Fate Therapeutics announces resignation of CFO Edward Dulac,5/31/2024 10:09:07 PM
FATE,Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference,5/29/2024 10:01:00 PM
FATE,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)",5/16/2024 10:17:09 AM
FATE,Hold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline Focus,5/14/2024 8:46:49 AM
FATE,"Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)",5/13/2024 10:20:46 AM
FATE,Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE),5/10/2024 12:47:01 PM
FATE,Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates,5/9/2024 10:01:00 PM
FATE,Fate Therapeutics Q1 2024 Earnings Preview,5/8/2024 9:35:57 PM
FATE,Forecasting The Future: 8 Analyst Projections For Fate Therapeutics,5/6/2024 6:00:42 PM
FATE,Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting,5/3/2024 10:30:00 PM
FATE,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)",4/24/2024 8:50:09 AM
FATE,Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting,4/22/2024 10:30:00 PM
FATE,Where Fate Therapeutics Stands With Analysts,4/11/2024 4:00:17 PM
FATE,"FATE, ALPN and RLAY are among after hour movers",4/10/2024 9:20:42 PM
FATE,Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference,4/3/2024 2:00:00 PM
FATE,Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4),4/2/2024 10:01:00 PM
FATE,Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns,3/28/2024 8:58:04 AM
FATE,Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV),3/26/2024 1:10:28 AM
FATE,"WPRT, FIVN and FATE are among after hour movers",3/25/2024 9:15:09 PM
FATE,"Fate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private Placement ",3/19/2024 2:31:21 PM
FATE,Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4),3/5/2024 10:01:00 PM
FATE,Fate Therapeutics to Present at Upcoming March Investor Conferences,3/1/2024 2:00:00 PM
FATE,Fate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical Data,2/28/2024 4:57:05 AM
FATE,Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics,2/27/2024 9:00:25 PM
FATE,Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates,2/26/2024 10:01:00 PM
FATE,Notable earnings after Monday's close,2/25/2024 10:35:04 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results,2/15/2024 2:00:00 PM
FATE,Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),2/2/2024 10:01:00 PM
FATE,Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock,1/29/2024 7:53:56 PM
FATE,Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors,1/8/2024 2:00:00 PM
FATE,"Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session",1/3/2024 12:14:35 PM
FATE,Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),12/13/2023 11:00:00 PM
FATE,"Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE), Wave Life Sciences (WVE) and HCA Healthcare (HCA)",11/10/2023 11:50:40 AM
FATE,Fate Therapeutics: Promising Developments and Buy Rating Justified by Clinical Trials and Financial Standing,11/9/2023 7:14:58 PM
FATE,TD Cowen Keeps Their Hold Rating on Fate Therapeutics (FATE),11/8/2023 11:55:50 PM
FATE,What Wall Street expects from Fate Therapeutics's earnings,11/7/2023 3:01:13 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results,10/25/2023 2:00:00 PM
FATE,Buy Rating Assigned to Fate Therapeutics: An Analysis of the Ono Program and Recent SITC Updates,9/29/2023 6:39:50 AM
FATE,"FATE, MVST and PAYO are among after hour movers",9/13/2023 9:07:09 PM
FATE,Analyst Ratings for Fate Therapeutics,9/7/2023 5:00:21 PM
FATE,Fate Therapeutics to Present at Upcoming September Investor Conferences,8/31/2023 2:00:00 PM
FATE,"MVIS, DHC and RUM are among after hour movers",8/28/2023 9:17:30 PM
FATE,The Latest Analyst Ratings for Fate Therapeutics,8/16/2023 7:01:02 PM
FATE,Fate Therapeutics (FATE) Gets a Hold from Robert W. Baird,8/11/2023 4:16:25 PM
FATE,Fate Therapeutics (FATE) Gets a Buy from Barclays,8/10/2023 7:26:29 AM
FATE,H.C. Wainwright Remains a Hold on Fate Therapeutics (FATE),8/9/2023 10:45:14 AM
FATE,"Fate Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $0.93M misses by $4.81M",8/8/2023 8:16:44 PM
FATE,Fate Therapeutics earnings preview: what Wall Street is expecting,8/7/2023 3:01:13 PM
FATE,Mizuho Securities Reaffirms Their Buy Rating on Fate Therapeutics (FATE),6/8/2023 10:15:32 PM
FATE,Where Fate Therapeutics Stands With Analysts,5/5/2023 5:02:19 PM
FATE,"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE) and NLS Pharmaceutics (NLSP)",5/4/2023 11:30:46 AM
FATE,Fate Therapeutics earnings preview: what Wall Street is expecting,5/2/2023 3:01:13 PM
FATE,$1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying,4/24/2023 2:59:37 PM
FATE,"FATE, GRTS and KZR are among after hour movers",3/28/2023 9:27:17 PM
FATE,15 Analysts Have This to Say About Fate Therapeutics,3/27/2023 10:01:04 PM
FATE,Biotech ETF XBI drops to an 8-month low,3/23/2023 12:56:52 PM
FATE,"ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE",3/18/2023 4:00:00 PM
FATE,"ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE",3/11/2023 4:30:00 PM
FATE,"ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE",3/4/2023 5:11:00 PM
FATE,"Analysts Conflicted on These Healthcare Names: Natera (NTRA), Mersana Therapeutics (MRSN) and Fate Therapeutics (FATE)",3/3/2023 5:30:39 AM
FATE,Expert Ratings for Fate Therapeutics,3/1/2023 9:01:26 PM
FATE,"Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M",2/28/2023 9:05:13 PM
FATE,Fate Therapeutics Q4 2022 Earnings Preview,2/27/2023 10:35:27 PM
FATE,"ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE",2/25/2023 9:02:00 PM
FATE,"ROSEN, A RESPECTED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE",2/18/2023 8:14:00 PM
FATE,"FATE, TVTX and IMAB are among after hour movers",2/17/2023 10:28:04 PM
FATE,"Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session",2/14/2023 12:13:32 PM
FATE,"Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session",2/13/2023 12:00:33 PM
FATE,"CRSR, FATE and PRTS are among after hour movers",2/10/2023 10:19:18 PM
FATE,"ROSEN, A LONGSTANDING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE",2/5/2023 3:00:00 PM
FATE,"ROSEN, A LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE",1/30/2023 8:39:00 PM
FATE,5 Cheapest Health Care Stocks You Should Think About,1/27/2023 2:48:06 PM
FATE,"ROSEN, A LEADING AND RANKED FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE",1/25/2023 12:36:00 AM
FATE,Analyst Ratings for Fate Therapeutics,1/24/2023 8:01:04 PM
FATE,5 Health Care Stocks That Are Diving - And May Rally,1/19/2023 2:58:28 PM
FATE,Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying,1/17/2023 3:04:20 PM
FATE,Mizuho Securities Reaffirms Their Buy Rating on Fate Therapeutics (FATE),1/11/2023 1:45:10 AM
FATE,Top 5 Health Care Stocks That May Surge,1/10/2023 1:34:00 PM
FATE,Robert W. Baird Keeps Their Hold Rating on Fate Therapeutics (FATE),1/9/2023 4:15:23 AM
FATE,"CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC",1/6/2023 8:48:56 PM
FATE,"Fate Therapeutics shares crater ~50% on ending tie-up with Janssen, layoffs",1/5/2023 10:42:21 PM
FATE,"Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday",1/4/2023 4:38:19 PM
FATE,Cathie Wood Loads Up Another $2M In Tesla While Elon Musk Urges Employees To Look Beyond Stock Plunge,12/29/2022 4:06:49 AM
FATE,"Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022",12/22/2022 4:00:36 PM
FATE,Fate Therapeutics extends losses as Goldman initiates at Sell,12/15/2022 5:20:09 PM
FATE,Needham Sticks to Its Hold Rating for Fate Therapeutics (FATE),12/14/2022 11:05:08 AM
FATE,SVB Securities Keeps Their Buy Rating on Fate Therapeutics (FATE),12/13/2022 12:25:13 PM
FATE,Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session,12/12/2022 7:05:03 PM
FATE,Fate Therapeutics (FATE) Gets a Buy from H.C. Wainwright,11/21/2022 11:25:10 AM
FATE,Needham Sticks to Their Hold Rating for Fate Therapeutics (FATE),11/14/2022 7:25:15 PM
FATE,Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors,11/7/2022 2:00:00 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,11/4/2022 9:01:00 PM
FATE,Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress,11/3/2022 9:01:00 PM
FATE,Fate Therapeutics is about to announce earnings — here's what Wall Street expects,11/2/2022 3:01:13 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results,10/24/2022 10:01:00 PM
FATE,Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting,10/5/2022 2:00:00 PM
FATE,7 Small-Cap Stocks to Buy Before September Ends,9/15/2022 3:54:49 PM
FATE,"Tesla, Meta, NVIDIA And Other Big Losers From Tuesday",9/14/2022 11:54:12 AM
FATE,Fate Therapeutics to Participate at Upcoming September Investor Conferences,9/2/2022 2:00:00 PM
FATE,"Apple, Amazon, HP And Other Big Losers From Friday",8/29/2022 11:12:03 AM
FATE,This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket,8/18/2022 1:23:25 PM
FATE,7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher,8/17/2022 1:29:22 PM
FATE,The 5 Top Stocks Cathie Wood Is Buying Now,8/15/2022 6:56:10 PM
FATE,Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock,8/12/2022 8:07:47 PM
FATE,Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells,8/9/2022 2:00:00 PM
FATE,7 Small-Cap Stocks to Buy Before the Bull Market Returns,8/7/2022 6:15:12 PM
FATE,Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress,8/3/2022 10:01:00 PM
FATE,Notable earnings after Wednesday's close (updated),8/2/2022 9:35:54 PM
FATE,Fate Therapeutics Initiated With Hold Rating - Read Why,7/28/2022 9:20:05 PM
FATE,7 Cathie Wood Stocks Trading at a Discount Right Now,7/26/2022 10:34:29 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results,7/25/2022 10:01:00 PM
FATE,"Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch",7/20/2022 4:28:00 PM
FATE,These stocks are on the most crowded shorts list - watch out above,7/19/2022 4:15:57 PM
FATE,"Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock",7/12/2022 7:44:15 PM
FATE,Expert Ratings for Fate Therapeutics,7/11/2022 11:12:59 PM
FATE,Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer,6/30/2022 10:01:00 PM
FATE,"Fate, Ono expand team up on cancer immunotherapy program",6/28/2022 1:19:52 PM
FATE,"Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022",6/3/2022 4:08:02 PM
FATE,"CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space",5/23/2022 4:58:50 PM
FATE,"BIOX, VECT and BBIO are among after hour movers",5/19/2022 9:54:02 PM
FATE,Fate Therapeutics to Present at Upcoming May Investor Conferences,5/6/2022 10:01:00 PM
FATE,Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress,5/4/2022 10:01:00 PM
FATE,Notable earnings after Wednesday's close,5/3/2022 9:35:38 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results,4/22/2022 2:00:00 PM
FATE,"SPRO,AMTI and BRZE among after hour movers",3/29/2022 9:49:30 PM
FATE,Cathie Wood’s ARKK suffers as two-thirds of its holdings fell to 52-week lows this week,3/17/2022 4:19:43 PM
FATE,What 4 Analyst Ratings Have To Say About Fate Therapeutics,3/4/2022 3:21:49 PM
FATE,Fate Therapeutics to Present at Upcoming March Investor Conferences,3/2/2022 10:01:00 PM
FATE,Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress,2/28/2022 10:01:00 PM
FATE,Notable earnings after Monday's close,2/27/2022 10:35:02 PM
FATE,"GDEN, IBRX and CHKEL among after hour movers",2/25/2022 10:56:02 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results,2/16/2022 2:00:00 PM
FATE,2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch,2/8/2022 9:03:43 PM
FATE,Fate Therapeutics to Present at Upcoming February Investor Conferences,2/2/2022 2:00:00 PM
FATE,Will the poor performance of biotechs in January be a barometer for 2022? Look to 2016,2/1/2022 6:57:20 PM
FATE,Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?,1/14/2022 10:32:44 PM
FATE,"Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors",1/10/2022 2:00:00 PM
FATE,Fate Therapeutics upgraded at Wedbush after data for off-the-shelf candidates,12/15/2021 7:30:23 PM
FATE,"The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks",12/14/2021 2:22:02 PM
FATE,Fate up 5% after hours on interim phase 1 data on B-cell lymphoma candidate,12/13/2021 11:19:36 PM
FATE,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",12/10/2021 8:00:40 PM
FATE,Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting,12/8/2021 11:44:52 PM
FATE,Fate Therapuetics rises 13% on outperform initiation from Cowen,12/7/2021 4:12:52 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,11/11/2021 2:00:00 PM
FATE,Fate Therapeutics upgraded at Citi on valuation ahead of key catalysts,11/9/2021 5:35:08 PM
FATE,Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress,11/4/2021 9:01:00 PM
FATE,Fate Therapeutics Q3 2021 Earnings Preview,11/3/2021 9:35:46 PM
FATE,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",10/31/2021 7:23:54 PM
FATE,Fate Therapeutics Inc hosts conference call for investors,10/29/2021 3:02:45 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results,10/25/2021 2:00:00 PM
FATE,3 Biotech Stocks to Watch Now,10/12/2021 5:08:54 PM
FATE,"IVAC, ERYP, CMTL and SABR among after hours movers",10/4/2021 9:39:58 PM
FATE,Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting,10/1/2021 2:01:00 PM
FATE, Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support,9/15/2021 2:00:00 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,9/2/2021 10:01:00 PM
FATE,"Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021",8/26/2021 4:04:12 PM
FATE,58 Biggest Movers From Friday,8/23/2021 11:06:17 AM
FATE,38 Stocks Moving In Friday's Mid-Day Session,8/20/2021 6:00:11 PM
FATE,"Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma",8/19/2021 10:01:00 PM
FATE,"The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow",8/15/2021 5:06:13 PM
FATE,Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress,8/4/2021 10:01:00 PM
FATE,Notable earnings after Wednesday's close,8/3/2021 9:35:34 PM
FATE,"Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy",8/2/2021 10:50:19 PM
FATE,"The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs",8/1/2021 4:13:48 PM
FATE,"Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma",7/16/2021 2:00:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results,7/15/2021 10:01:00 PM
FATE,"Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says",7/11/2021 1:00:00 PM
FATE,7 Stocks to Buy Now if You’re Feeling Greedy While Others Are Fearful,6/24/2021 2:01:17 PM
FATE,Fate Therapeutics is expected to dominate in cell therapy despite Gilead’s entry,6/17/2021 7:15:59 PM
FATE,"Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer",6/15/2021 2:00:00 PM
FATE,"Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021",6/7/2021 4:02:41 PM
FATE,Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting,6/4/2021 1:00:00 PM
FATE,"The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes",5/31/2021 5:06:35 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,5/25/2021 10:01:00 PM
FATE,Biotech M&A could soon pick up following slow 2021 start - Jefferies,5/23/2021 7:25:39 PM
FATE,"Drug pricing in focus at Citi, 1Life earns another bull at Keybanc, and more in today’s analyst action",5/21/2021 12:45:14 PM
FATE,"Heron defended after yesterday's plunge, Aurora Cannabis earns mixed reactions after Q3 results - today's healthcare analyst action",5/14/2021 12:50:44 PM
FATE,Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia,5/13/2021 10:01:00 PM
FATE,Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat,5/12/2021 7:05:05 AM
FATE,"Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings",5/11/2021 5:07:42 AM
FATE,Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com,5/10/2021 3:49:50 AM
FATE,"The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings",5/9/2021 4:20:33 PM
FATE,Seeking Alpha Catalyst Watch,5/7/2021 7:30:30 PM
FATE,Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress,5/5/2021 10:01:00 PM
FATE,Notable earnings after Wednesday's close,5/4/2021 9:35:29 PM
FATE,Fate Therapeutics earnings preview: what Wall Street is expecting,5/3/2021 3:01:44 PM
FATE,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,4/29/2021 6:10:51 PM
FATE,Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting,4/27/2021 10:31:00 PM
FATE,"HCA Healthcare downgraded despite strong Q1 results, LHC Group becomes a new catalyst call; and more in today’s analyst action",4/26/2021 1:00:13 PM
FATE,"Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square",4/13/2021 7:56:45 AM
FATE,Seeking Alpha Catalyst Watch,4/9/2021 5:30:00 PM
FATE,"LendingClub, Trimble, ICE, Fate Therapeutics — What Cathie Wood's Ark Bought And Sold On Tuesday",4/7/2021 4:01:50 AM
FATE,"Twitter, Trimble, 908 Devices, Tencent, Pluristem — What Cathie Wood's Ark Bought And Sold On Monday",4/6/2021 4:04:56 AM
FATE,"Pinduoduo, Shopify, PayPal, LendingTree, JD.com — What Cathy Wood's Ark Bought And Sold On Wednesday",4/1/2021 4:54:24 AM
FATE,"Facebook, Twilio, Spotify, PayPal, Unity — What Cathie Wood's Ark Bought And Sold On Tuesday",3/31/2021 5:02:54 AM
FATE,"Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday",3/30/2021 6:03:55 AM
FATE,"Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday",3/26/2021 6:00:46 AM
FATE,Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service,3/25/2021 12:00:00 PM
FATE,"TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today",3/24/2021 4:52:52 AM
FATE,7 ARKK Stocks With Technical Support And Upside Potential,3/13/2021 1:23:28 PM
FATE,7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines,3/12/2021 4:54:49 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,3/8/2021 1:00:00 PM
FATE,Fate Therapeutics initiated buy at BofA despite early-stage pipeline,2/26/2021 5:04:04 PM
FATE,Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress,2/24/2021 10:01:00 PM
FATE,Notable earnings after Wednesday's close,2/23/2021 10:35:55 PM
FATE,Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference,2/22/2021 10:01:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results,2/19/2021 2:00:00 PM
FATE,Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity,1/16/2021 8:22:05 PM
FATE,"The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges",1/15/2021 1:32:12 PM
FATE,"Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares",1/8/2021 10:26:19 PM
FATE,80 Biggest Movers From Yesterday,1/7/2021 12:04:30 PM
FATE,Fate Therapeutics prices equity offering and pre-funded warrants,1/6/2021 11:47:15 AM
FATE,"The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data",1/5/2021 2:38:54 PM
FATE,Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock,1/4/2021 10:01:00 PM
FATE,"BLCM Hit With Clinical Hold, LANTERN Fails To Light Up LYRA, TNXP Gains, FDA Says No To SCPH ",12/8/2020 7:53:15 AM
FATE,"KODK, TNXP, SNDL and MBIO among midday movers",12/7/2020 5:41:10 PM
FATE,Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma,12/6/2020 4:05:00 PM
FATE,"RIDE, FATE, MBIO and MRIN among after-hours movers",12/4/2020 10:52:08 PM
FATE,"BCRX Awaits FDA Decision, JNJ On Watch, Pfizer/BioNTech's COVID-19 Vaccine Gets Green Light In UK ",12/3/2020 6:37:33 AM
FATE,Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting,11/30/2020 2:00:00 PM
FATE,Fate Therapeutics Announces Participation in Upcoming Investor Conferences,11/12/2020 10:01:00 PM
FATE,Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress,11/5/2020 10:01:00 PM
FATE,Notable earnings after Thursday's close,11/4/2020 10:35:58 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results,11/2/2020 1:00:00 PM
FATE,Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting,10/15/2020 2:00:10 PM
FATE,"CORR, FATE, AKBA and DPW among after-hours movers",10/9/2020 9:41:46 PM
FATE,Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit,9/30/2020 2:00:10 PM
FATE,Fate Therapeutics Announces September Investor Events,9/4/2020 2:00:10 PM
FATE,Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer,8/19/2020 2:00:10 PM
FATE,Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress,8/5/2020 10:01:10 PM
FATE,Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference,8/4/2020 10:01:10 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results,7/29/2020 10:01:10 PM
FATE,Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies,7/14/2020 2:00:10 PM
FATE,Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy,7/9/2020 2:00:10 PM
FATE,Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,6/11/2020 10:01:10 PM
FATE,"DNLI Halts DNL747 Development, IMRN Skyrockets, XENT's Sinus Implant Gets New C-Code ",6/10/2020 7:19:07 AM
FATE,Fate Therapeutics among healthcare gainers; GNC and Cerecor among losers,6/9/2020 3:03:56 PM
FATE,Fate Therapeutics Announces Proposed Public Offering of Common Stock,6/8/2020 10:01:10 PM
FATE,"Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy",5/20/2020 2:00:10 PM
FATE,Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress,5/11/2020 10:01:10 PM
FATE,Fate Therapeutics Q1 2020 Earnings Preview,5/10/2020 9:35:50 PM
FATE,Fate Therapeutics Announces Changes to its Board of Directors,5/5/2020 10:01:10 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results,5/4/2020 10:01:10 PM
FATE,Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting,4/28/2020 10:30:10 PM
FATE,Healthcare - Top 5 Gainers / Losers,4/3/2020 3:04:36 PM
FATE,Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies,4/2/2020 10:46:00 PM
FATE,Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook,3/2/2020 10:01:00 PM
FATE,Notable earnings after Monday's close,3/1/2020 10:35:51 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results,2/26/2020 2:00:00 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,2/7/2020 2:00:00 PM
FATE,Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood,1/13/2020 2:00:00 PM
FATE,3 Top Drug Stocks to Own In 2020,1/3/2020 3:44:20 PM
FATE,"Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting",12/10/2019 3:51:56 PM
FATE,"Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy",12/8/2019 4:39:49 PM
FATE,"Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs",12/7/2019 2:40:25 PM
FATE,Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference,11/27/2019 10:01:10 PM
FATE,Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference,11/14/2019 10:01:00 PM
FATE,Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting,11/6/2019 3:01:00 PM
FATE,Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress,11/5/2019 10:05:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results,10/29/2019 9:01:05 PM
FATE,Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies,9/30/2019 2:00:00 PM
FATE,Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares,9/18/2019 10:01:00 PM
FATE,Fate Therapeutics Announces Pricing of Public Offering of Common Stock,9/12/2019 6:53:30 AM
FATE,Fate Therapeutics Announces Proposed Public Offering of Common Stock,9/11/2019 10:01:00 PM
FATE,"Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy",9/3/2019 2:01:00 PM
FATE,Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference,8/29/2019 2:00:00 PM
FATE,Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells,8/14/2019 2:00:00 PM
FATE,Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress,8/6/2019 10:01:00 PM
FATE,Fate Therapeutics earnings preview: what to expect,8/4/2019 3:01:57 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2019 Financial Results,7/30/2019 10:01:00 PM
FATE,Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors,7/17/2019 10:01:00 PM
FATE,Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference,5/30/2019 10:05:00 PM
FATE,Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress,5/7/2019 10:01:00 PM
FATE,What Wall Street expects from Fate Therapeutics's earnings,5/5/2019 3:01:51 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results,4/30/2019 10:05:00 PM
FATE,Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting,4/24/2019 2:00:00 PM
FATE,"Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development",4/18/2019 2:01:00 PM
FATE,Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment,4/2/2019 2:00:00 PM
FATE,Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting,4/1/2019 2:01:00 PM
FATE,"Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors",3/18/2019 1:00:00 PM
FATE,Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress,3/5/2019 10:01:00 PM
FATE,Fate Therapeutics earnings: here's what Wall Street expects,3/3/2019 3:01:21 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results,2/28/2019 10:43:34 PM
FATE,Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference,2/22/2019 2:00:00 PM
FATE,"Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation",2/20/2019 2:00:00 PM
FATE,Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day,2/7/2019 10:01:00 PM
FATE,Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell,2/6/2019 2:00:00 PM
FATE,Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting,12/4/2018 3:11:02 PM
FATE,Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products,12/3/2018 10:01:00 PM
FATE,"Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy",11/30/2018 2:00:00 PM
FATE,Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500,11/11/2018 11:42:14 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,11/8/2018 10:01:00 PM
FATE,Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress,11/1/2018 9:01:00 PM
FATE,Here's what Wall Street expects from Fate Therapeutics's earnings,10/30/2018 3:03:29 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results,10/29/2018 9:01:00 PM
FATE,"FATE Catches Eyes, LJPC Upbeat, CLSD To Submit XIPERE NDA By Year-end ",10/26/2018 3:03:50 AM
FATE,"Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations",10/4/2018 2:00:00 PM
FATE,Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,9/25/2018 10:01:00 PM
FATE,Fate Therapeutics Announces Pricing of Public Offering of Common Stock,9/21/2018 5:37:41 AM
FATE,Fate Therapeutics Announces Proposed Public Offering of Common Stock,9/20/2018 10:11:02 PM
FATE,"Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies",9/18/2018 1:00:00 AM
FATE,Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming,9/13/2018 2:00:00 PM
FATE,Fate Therapeutics to Present at Upcoming Investor Conferences,8/29/2018 10:01:00 PM
FATE,Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference,8/7/2018 10:01:00 PM
FATE,Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress,8/6/2018 10:01:00 PM
FATE,Here's what to expect from Fate Therapeutics's earnings,8/4/2018 3:01:29 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results,7/30/2018 10:01:00 PM
FATE,Fate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference,6/1/2018 10:01:00 PM
FATE,Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell ImmunotherapiesDr. Michel Sadelain to Present Preclinical Data from...,5/16/2018 2:00:00 PM
FATE,Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress,5/10/2018 10:01:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results,5/3/2018 10:01:00 PM
FATE,Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference,5/2/2018 2:00:00 PM
FATE,Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program,4/16/2018 3:30:00 PM
FATE,"CBAY Walks The Talk, MYND Explodes, NITE Sparkles, NVLN Awaits CHMP Opinion ",4/12/2018 3:11:02 AM
FATE,Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018Stable Disease with Tumor Shrinkage Reported in Subject 2 Following...,3/29/2018 2:00:00 PM
FATE,Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™,3/19/2018 1:00:00 PM
FATE,Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress,3/5/2018 10:01:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results,2/27/2018 2:00:00 PM
FATE,Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy$4.0 Million Awarded by CIRM to Support Advancement of...,2/23/2018 2:00:00 PM
FATE,"ANTH Awaits RESULT In Mar., HAIR Grows, NITE Shines, TRXC On Must-watch List ",2/22/2018 3:04:14 AM
FATE,Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid TumorsFirst Clinical Trial Investigating the Combination of Allogeneic Donor NK Cell Therapy...,2/20/2018 2:00:00 PM
FATE,Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference,2/12/2018 10:01:00 PM
FATE,"CERC Down But Not Out, EYEG To Report Data In Q2, MRSN On Watch ",12/29/2017 5:33:18 AM
FATE,"Busy Year Awaits INSY, Agile Not So Energetic, FATE Gathers Steam, SRRA On Watch ",12/27/2017 1:35:34 AM
FATE,"APLS Sets Out Its Vision, APEN Gains Weight, Packed Year Ahead For DRNA ",12/22/2017 2:04:16 AM
FATE,Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,12/15/2017 10:01:00 PM
FATE,Fate Therapeutics Announces Pricing of Public Offering of Common Stock,12/13/2017 2:00:00 PM
FATE,Fate Therapeutics Announces Proposed Public Offering of Common Stock,12/12/2017 10:01:00 PM
FATE,Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500,12/11/2017 10:30:31 PM
FATE,"Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy",12/9/2017 6:30:00 PM
FATE,Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer,12/8/2017 10:01:00 PM
FATE,Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies,12/6/2017 2:00:00 PM
FATE,"ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV ",12/5/2017 1:04:33 PM
FATE,Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference,11/21/2017 2:00:00 PM
FATE,Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting,11/10/2017 2:00:00 PM
FATE,Fate Therapeutics Reports Third Quarter 2017 Financial Results,11/1/2017 9:01:00 PM
FATE,Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results,10/25/2017 10:01:00 PM
FATE,Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease,9/18/2017 2:00:00 PM
FATE,"Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development",9/14/2017 2:00:00 PM
FATE,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR ",8/30/2017 5:18:07 AM
FATE,"FDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials ",8/15/2017 7:37:49 AM
